Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany-Reference-Cited by-同舟云学术

Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany

Published:2015-10-22 Issue:6 Volume:46 Page:1826-1829
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:Eur Respir J

Author:

Wolfson Lara J.,Gibbert Judith,Wirth Daniel,Diel Roland

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference26 articles.

1. Issues Facing TB Control (7) Multiple Drug-Resistant Tuberculosis

2. XDR Tuberculosis — Implications for Global Public Health

3. World Health Oganization. Global Tuberculosis Report 2014. Geneva, World Health Oganization, 2014.

4. Empfehlungen zur Therapie, Chemoprävention und Chemoprophylaxe der Tuberkulose im Erwachsenen- und Kindesalter

5. Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2012. www.rki.de/DE/Content/InfAZ/T/Tuberkulose/Download/TB2012.html Date last accessed: March 17, 2015. Date last updated: March 17, 2014.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China;BIOMED ENVIRON SCI;2023

2. Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2022-10-09

3. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines;BMJ Open;2021-12

4. A systematic review of pharmacoeconomic evaluations on oral diarylquinoline-based treatment for drug-resistant tuberculosis: from high to low burden countries;Expert Review of Pharmacoeconomics & Outcomes Research;2021-06-23

5. PERSPECTIVES OF TARGETED CHEMOTHERAPY WITH DELAMANID IN THE TREATMENT REGIMENS OF THOSE WITH MULTIPLE/EXTENSIVE DRUG RESISTANT TUBERCULOSIS. A SUCCESS, CHANCE OR UNCERTAINTY?;TUBERCULOSIS AND LUNG DISEASES;2018